Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
AARDthis companyAardvark Therapeutics, Inc. Common Stock	$1.33	-4.97×	2.69×	0×	-4.17×	71.6%	0.0%	0.0%	0.0%	-54.0%	-58.6%	-18.9%	0×	0.81×	0×	10.61×	0.0%	1	-1.98	3	B-
ASMBAssembly Biosciences, Inc.	$20.95	-61.84×	1.84×	5.27×	-54.31×	-382.4%	99.8%	-16.8%	-8.5%	-3.0%	-5.8%	-10.8%	0.01×	9.31×	0×	5.22×	0.0%	2	7.22	2	B-
AVTXAvalo Therapeutics, Inc.	$7.02	-3.11×	2.93×	4,125.96×	-2.96×	-86.5%	100.0%	-123601.7%	-132642.4%	-94.2%	-70.2%	-21.1%	0.03×	0.17×	0×	8.14×	0.0%	2	4.43	2	B-
CRBUCaribou Biosciences, Inc.	$0.45	-1×	1.22×	13.31×	-1.13×	-908.6%	67.3%	-1220.5%	-1327.4%	-121.2%	-89.8%	-75.7%	0.22×	-0.1×	0×	5.71×	0.0%	3	-7.25	2	C
ENTAEnanta Pharmaceuticals, Inc.	$11.49	-3.12×	3.95×	3.91×	-5.99×	-669.1%	93.0%	-130.7%	-125.4%	-126.5%	-31.4%	-12.6%	3.11×	-2.38×	-11.11×	4.21×	0.0%	3	-0.92	1	C-
FHTXFoghorn Therapeutics Inc.	$1.98	-4.58×	-3.13×	11×	-4.24×	-713.4%	89.2%	-265.6%	-240.3%	68.5%	-58.9%	-25.3%	-0.38×	0.56×	0×	2.73×	0.0%	3	-4.44	2	C
Peer median	—	-3.12×	1.84×	11×	-4.24×	-669.1%	93.0%	-265.6%	-240.3%	-94.2%	-58.9%	-21.1%	0.03×	0.17×	0×	5.22×	0.0%	3	-0.92	2	—